Actavia Life Sciences, Inc. financial data

Symbol
RASP on OTC
Location
5 Penn Plaza, 19 Th Floor, #1954, New York, NY
State of incorporation
Nevada
Fiscal year end
September 30
Former names
Rasna Therapeutics Inc. (to 8/14/2023), Active With Me Inc. (to 9/26/2016)
Latest financial report
10-Q - Q1 2024 - May 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -103 %
Return On Equity 19.8 % -92.9%
Return On Assets -784 % +89.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 772M shares 0%
Common Stock, Shares, Outstanding 772M shares +8.43%
Entity Public Float 1.71M USD -12.5%
Common Stock, Value, Issued 772K USD 0%
Weighted Average Number of Shares Outstanding, Basic 772M shares +31.1%
Weighted Average Number of Shares Outstanding, Diluted 772M shares +31.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 90.3K USD +1.33%
General and Administrative Expense 255K USD -15.1%
Operating Income (Loss) -345K USD +91.9%
Net Income (Loss) Attributable to Parent -407K USD +91.8%
Earnings Per Share, Basic -0.01 USD/shares 0%
Earnings Per Share, Diluted -0.01 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets 48.6K USD -7.04%
Accounts Payable, Current 960K USD +16.7%
Accrued Liabilities, Current 499K USD -5.79%
Liabilities, Current 2.23M USD +16%
Liabilities 2.05M USD +15.7%
Retained Earnings (Accumulated Deficit) -28.9M USD -1.43%
Stockholders' Equity Attributable to Parent -2.18M USD -16.7%
Liabilities and Equity 48.6K USD -7.04%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -47.3K USD -3302%
Net Cash Provided by (Used in) Financing Activities -8.51K USD -189%
Common Stock, Shares Authorized 1.5B shares 0%
Common Stock, Shares, Issued 772M shares +8.43%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.39K USD -37.3%
Deferred Tax Assets, Valuation Allowance 2.86M USD -13.8%
Deferred Tax Assets, Gross 2.86M USD -13.8%
Deferred Tax Assets, Operating Loss Carryforwards 2.12M USD -21.1%
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 26M USD +0.37%
Interest Expense 19.3K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%